Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Finance

Zimmer Biomet forecasts 2025 profit below estimates

Published by Global Banking and Finance Review

Posted on February 6, 2025

Featured image for article about Finance

(Reuters) - Medical device maker Zimmer Biomet Holdings forecast full-year adjusted profit below Wall Street estimates on Thursday, as it anticipates a hit from a strong dollar.

The company expects 2025 adjusted profit to be in the range of $8.15 to $8.35 per share, compared with the average of analysts' expectations of $8.56 per share, according to data compiled by LSEG. The company expects a 1.5% to 2% negative impact from currency swings on its revenue this year.

However, the company's fourth-quarter profit and revenue both came in slightly above expectations, due to strong demand for its devices used in hip and knee procedures.

Combined sales at Zimmer's hips and knees units came in at $1.36 billion, compared to $1.30 billion, a year ago.

Sales at its unit that sells sports medicine and trauma care products came in at $489.4 million, compared to $453.3 million, a year ago.

Brokerage Evercore ISI says that the forecast is already lower than expected and Zimmer's acquisition of orthopedic surgical devices maker Paragon 28, announced last month, could further reduce earnings by another 10 cents.

In the fourth quarter, the company posted a profit of $2.31 per share, beating estimates by 1 cent.

Zimmer's total sales for the reported quarter came in at $2.02 billion, compared with analysts' estimates of $2.01 billion.

(Reporting by Kamal Choudhury in Bengaluru; Editing by Leroy Leo)